NRXP (NRx Pharmaceuticals Inc.) מחיר לרווח עתידי

לוגו גרפי של NRx Pharmaceuticals (NRXP)

Demand for psychiatric care is independent of economic cycles, making the NRx Pharmaceuticals (NRXP) business resilient. The company's forward P/E ratio visualizes market expectations, with the latest mark standing at 0.00. Asset value growth is driven by the expansion of the drug NRX-101, while raw material supply reliability eliminates logistical disruptions, ensuring a stable commercial launch of new products.

שווי שוק לרווח חזוי: NRx Pharmaceuticals Inc. (NRXP) עבור 04.07.2022 - 17.11.2026

פילוחי מדדים ואנליטיקה של חברת NRx Pharmaceuticals (NRXP)

- מחיר נוכחי ושווי מניות חזוי:
- מדדי הערכת שווי שוק של העסק:
הערכת שווי פונדמנטלית:NRXP nrxpharma.com
פריט של המותג NRx Pharmaceuticals, Inc

When screening assets, investors utilize the projected stock price relative to expected earnings to determine the extent of the premium paid for future growth. This forward P/E multiple for NRx Pharmaceuticals (NRXP) relates current market capitalization to upcoming revenues from innovative CNS therapy and pneumonia treatments, allowing a chart analysis to assess market expectations for the commercialization of breakthrough life-saving methods.